In the ATHENA‐HF trial, there was no difference in 3‐day NT‐proBNP or 30‐day mortality or HHF with in‐hospital use of high‐dose spironolactone (100 mg daily) as compared to usual care alone among patients with stabilized AHF regardless of baseline LVEF.71 This evidence concerns the gene NPPB and hydrops fetalis.